About us
Company Director Jenny (Jennifer) Walsh is a PhD UK-registered pharmacist with over 25 years’ experience in the pharmaceutical and consumer healthcare industries (Glaxo SmithKline, Napp Research Centre, The Boots Company, Reckitt Benckiser, AstraZeneca), where she held a variety of roles within Pharmaceutical Development and Medical Affairs.
She specialises in the development of age-appropriate paediatric medicines and has actively contributed to numerous global paediatric development projects, including Paediatric Investigation Plans (PIPs) and Pediatric Study Plans (PSPs).
In addition to supporting the paediatric formulation of new chemical entities and off patent drugs for pharmaceutical companies, Jenny works with non-profit organisations on global paediatric medicines projects.
Jenny is a founder member of and a subject matter expert for the European Paediatric Formulation Initiative (EuPFI, http://www.eupfi.org/), and an advisor to “conect4children” European network (Work Package 4; Scientific advice, feasibility & innovation) (https://conect4children.org/).
Membership of Professional Organisations
- The Royal Pharmaceutical Society of Great Britain
- American Association of Pharmaceutical Scientists
- General Pharmaceutical Council
- European Paediatric Formulation Initiative
- Neonatal and Paediatric Pharmacists Group
Publications
-
Usability of administration devices for oral and respiratory medicines: Views from a UK primary school. Eur J Pharm Biopharm (2022) 178:150-158
-
Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper. BJCP (2022) 88:5034-5051
-
A Survey to Understand Parent/Caregiver and Children’s Views on Devices Used for the Administration of Oral Pediatric Medicines in Japan. Children (2022) 9:196
-
Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool. Pharmaceutics (2022) 14:473
-
Proposed Tool to Compare and Assess the Applicability of Taste Assessment Techniques for Pharmaceuticals. J Pharm Sci (2022) 111:1219-1223
-
Pediatric formulation development – Challenges of today and strategies for tomorrow: Summary report from M−CERSI workshop 2019. Eur J Pharm Biopharm (2021) 164:54-65
-
Innovative delivery systems for paediatric medicines: technology landscape. Geneva: World Health Organization; Unitaid (partnership hosted by the World Health Organization); 2020 https://unitaid.org/assets/Innovative-delivery-systems-for-paediatric-medicines-technology-landscape.pdf
-
Age-appropriate solid oral formulations for pediatric applications with a focus on multiparticulates and minitablets: Summary of September 2019 EuPFI workshop. Eur J Pharm Biopharm (2020) 153:222-225
-
Pharmacology of enalapril in children: a review. Drug Discov Today (2020) 25(11):1957-1970
- European Paediatric Formulation Initiative Workshop Report: Improving the Administration of Oral Liquid Medicines in Paediatrics using Dosing Syringes and Enteral Accessories. Eur J Pharm Biopharm (2020) 151: 91-97
- Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings. Pharmaceutics (2019) 11(10): 518
- Pharmacotherapy in paediatric heart failure: a Delphi process. Cardiology in the Young (2019) 29(7): 1-8
- Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study. Contemporary Clinical Trials Communication (2019) 15: 1000393
- Pharmacotherapeutic management of paediatric heart failure and ACE-I use patterns: a European survey. BMJ Paediatrics Open (2019) 3(1): e000365
- Flexible and precise dosing of enalapril maleate for all paediatric age groups utilizing orodispersible minitablets. Int. J. Pharm. (2018) 541: 136-142
- Methodologies for assessing the acceptability of oral formulations among children and older adults: a systematic review. Drug Disc. Today (2018) 23: 830-847
- Patient acceptability, safety and access: A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations. Int. J. Pharm. (2018) 536: 547-562
- European Paediatric Formulation Initiative (EuPFI) - Formulating ideas for better medicines for children. AAPS PharmSciTech (2017) 18: 257-262
- Reflection on the pharmaceutical formulation challenges associated with a Paediatric Investigation Plan for an off-patent drug. AAPS PharmSciTech (2017) 18: 250-256
- Devices for oral and respiratory medicines: What do healthcare professionals think? Int. J. Pharm. (2015) 492: 304-315.
- Playing hide and seek with poorly tasting paediatric medicines: do not forget the excipients. Adv. Drug Del. Rev. (2014) 73: 14-33.
- Challenges and recent developments in administration devices for paediatrics. BioPharma Asia (2014) 3 (6).
- Formulating better medicines for children: 4th EuPFI Conference. Therapeutic Delivery (2013) 4: 21-25.
- A benefit/risk approach towards selecting appropriate pharmaceutical dosage forms - An application for paediatric dosage form selection. Int. J. Pharm. (2012) 435: 115-123.
- Excipients for the formulation of medicines for children European Industrial Pharmacy (2012) Issue 13: 14-16.
- Delivery Devices for the Administration of Paediatric Formulations: Overview of Current Practice, Challenges and Recent Developments. Int. J. Pharm. (2011) 415: 221-231.
About Us
Company Director Jenny (Jennifer) Walsh is a PhD UK-registered pharmacist ...
Find out moreCase Studies
Working as a "virtual" project team member in collaboration with the client ...
Find out moreTestimonials
Take a look at some of our reviews from our clients and our happy customers.
Find out more